Summit Therapeutics Presents Positive Ivonescimab Data at ELCC 2026
Event summary
- Summit Therapeutics will present three posters on ivonescimab at ELCC 2026, including Phase III data from HARMONi and HARMONi-2 studies.
- Ivonescimab plus chemotherapy showed a 10.1-month intracranial PFS improvement in EGFR-mutated NSCLC patients with brain metastases (vs. 6.5 months for chemotherapy alone).
- HARMONi-2 data compares ivonescimab monotherapy to pembrolizumab in PD-L1 positive NSCLC, conducted exclusively in China by Akeso.
- Summit submitted a BLA for ivonescimab in EGFR-mutated NSCLC; FDA target action date is November 14, 2026.
The big picture
Summit’s presentation of positive Phase III data for ivonescimab underscores the growing competition in immuno-oncology, particularly in NSCLC. The bispecific antibody’s dual-targeting mechanism (PD-1 + VEGF) could differentiate it from existing therapies if regulatory and commercial hurdles are cleared. Summit’s partnership with Akeso expands its reach into China, a critical market for oncology innovation.
What we're watching
- Regulatory Pathway
- Whether the FDA will approve ivonescimab by the November 2026 PDUFA date, given the positive Phase III data.
- Commercial Strategy
- How Summit plans to position ivonescimab against established therapies like pembrolizumab in global markets.
- Pipeline Expansion
- The pace at which Summit advances ivonescimab into additional indications beyond NSCLC, including CRC and HNSCC.
Related topics